Intellia Therapeutics (NTLA) News Today $9.45 -0.64 (-6.34%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$9.59 +0.14 (+1.43%) As of 03/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Q1 Earnings Estimate for NTLA Issued By Leerink PartnrsMarch 4 at 2:05 AM | americanbankingnews.comIntellia Therapeutics price target lowered to $50 from $90 at TruistMarch 4 at 12:18 AM | markets.businessinsider.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) ShareholdersMarch 3 at 1:17 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLAMarch 3 at 12:50 PM | prnewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud LawsuitMarch 3 at 11:09 AM | prnewswire.comNTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. ...March 3 at 6:43 AM | gurufocus.comNTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 3 at 5:45 AM | prnewswire.comWhat is William Blair's Forecast for NTLA FY2029 Earnings?Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at William Blair issued their FY2029 earnings per share estimates for Intellia Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will earn $2.96 pMarch 3 at 3:46 AM | marketbeat.comNTLA FY2027 EPS Lifted by Brookline Capital ManagementIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Brookline Capital Management raised their FY2027 EPS estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann now anticipaMarch 3 at 3:46 AM | marketbeat.comCitigroup Increases Intellia Therapeutics (NASDAQ:NTLA) Price Target to $14.00March 3 at 3:17 AM | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at Wells Fargo & CompanyMarch 3 at 3:17 AM | americanbankingnews.comWhat is Leerink Partnrs' Forecast for NTLA Q1 Earnings?Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Intellia Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earningMarch 3 at 1:48 AM | marketbeat.comBank of America Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)March 3 at 12:22 AM | markets.businessinsider.comBarclays Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceMarch 2 at 2:33 AM | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 9.6% on Analyst DowngradeMarch 2 at 1:23 AM | americanbankingnews.comIntellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call TranscriptMarch 2 at 12:43 AM | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 9.6% After Analyst DowngradeIntellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6% Following Analyst DowngradeMarch 1 at 7:13 PM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Given New $26.00 Price Target at BarclaysBarclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday.March 1 at 5:13 PM | marketbeat.comROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAMarch 1 at 2:58 PM | investing.comCitigroup Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceCitigroup lifted their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research report on Friday.March 1 at 2:15 PM | marketbeat.comWells Fargo & Company Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $50.00Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday.March 1 at 12:54 PM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $68.00 by Analysts at Chardan CapitalChardan Capital lowered their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a research note on Friday.March 1 at 10:47 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Sell Rating from The Goldman Sachs GroupThe Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday.March 1 at 8:11 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Given "Neutral" Rating at JPMorgan Chase & Co.JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday.March 1 at 8:11 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Estimates By $0.08 EPSIntellia Therapeutics (NASDAQ:NTLA - Get Free Report) released its earnings results on Thursday. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.08.March 1 at 12:19 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Posts Earnings Results, Beats Expectations By $0.08 EPSIntellia Therapeutics (NASDAQ:NTLA - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.08.February 28, 2025 | marketbeat.comJP Morgan Downgrades Intellia Therapeutics (NTLA)February 28, 2025 | msn.comMorgan Stanley Keeps Their Hold Rating on Intellia Therapeutics (NTLA)February 28, 2025 | markets.businessinsider.comIntellia Therapeutics (NASDAQ:NTLA) Trading 9.7% Higher After Earnings BeatIntellia Therapeutics (NASDAQ:NTLA) Trading 9.7% Higher Following Strong EarningsFebruary 28, 2025 | marketbeat.comIntellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...February 28, 2025 | finance.yahoo.comIntellia Therapeutics price target lowered to $50 from $60 at Wells FargoFebruary 28, 2025 | markets.businessinsider.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Generali Investments Towarzystwo Funduszy InwestycyjnychGenerali Investments Towarzystwo Funduszy Inwestycyjnych increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6February 28, 2025 | marketbeat.comApril 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLAFebruary 28, 2025 | prnewswire.comIntellia Therapeutics price target raised to $14 from $12 at CitiFebruary 28, 2025 | markets.businessinsider.comIntellia Therapeutics’ Earnings Call: Progress and ChallengesFebruary 28, 2025 | msn.comIntellia Therapeutics downgraded to Neutral from Overweight at JPMorganFebruary 28, 2025 | markets.businessinsider.comROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAFebruary 27, 2025 | globenewswire.comClass Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – Contact Levi & KorsinskyFebruary 27, 2025 | globenewswire.comIntellia Therapeutics Delivers a Q4 BeatFebruary 27, 2025 | fool.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia TherapeuticsFebruary 27, 2025 | prnewswire.comIntellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company ProgressFebruary 27, 2025 | globenewswire.comThe Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLAFebruary 27, 2025 | prnewswire.comRobbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their LossesFebruary 26, 2025 | prnewswire.comNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 26, 2025 | globenewswire.comShareholders of Intellia Therapeutics, Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – NTLAFebruary 26, 2025 | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia TherapeuticsFebruary 26, 2025 | markets.businessinsider.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Lifted by ARK Investment Management LLCARK Investment Management LLC raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,536,386 shares of theFebruary 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLAFebruary 25, 2025 | prnewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmFebruary 25, 2025 | prnewswire.comInvestors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLAFebruary 25, 2025 | prnewswire.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.210.70▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼618▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News SpringWorks Therapeutics News Organon & Co. News Ultragenyx Pharmaceutical News PTC Therapeutics News ADMA Biologics News Avidity Biosciences News Zai Lab News Biohaven News Alvotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts